Oncology

Afify A, McNiel MA, Braggin J, Bailey H, Paulino AF. 2008. Expression of CD44s, CD44v6, and Hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast. Appl Immunohistochem Mol Morphol [epub ahead of print].

Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, Grove B, Dye A, Bridger G. 2008. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: Compassionate use data. Bone Marrow Transplant 41:331-338.

Guyre CA, Gomes D, Smith KA, Kaplan JM, Perricone MA. 2008. Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies. J Immunol Methods

Shtilbans V, Wu M, Burstein DE. 2008. Current overview of the role of Akt in cancer studies via applied immunohistochemistry. Ann Diagn Pathol 12:153-160.

Teicher BA. 2008. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75:1262-1271.

Bonate PL, Beyerlein D, Crawford J, Roth S, Krumbholz R, Schmid S. 2007. Pharmacokinetics in mice implanted with xenografted tumors after intravenous administration of tasidotin (ILX651) or its carboxylate metabolite. AAPS J 9:E378-387.

Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, Grove B, Dye A, Bridger G. 2007. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant [epub ahead of print].

Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS. 2007. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma 48:2424-2436.

Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. 2007. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557-563.

Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C. 2007. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178:2883-2892

Morgenbesser SD, McLaren RP, Richards B, Zhang M, Akmaev VR, Winter SF, Mineva ND, Kaplan-Lefko PJ, Foster BA, Cook BP, Dufault MR, Cao X, Wang CJ, Teicher BA, Klinger KW, Greenberg NM, Madden SL. 2007. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate 67:83-106.

Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL. 2007. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath((R))) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol.

Teicher BA. 2007. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol.

Teicher BA. 2007. Newer vascular targets: endosialin (review). Int J Oncol 30:305-312.

Teicher BA. 2007. Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res 13:6247-6251.

Anscher MS, Thrasher B, Rabbani Z, Teicher B, Vujaskovic Z. 2006. Antitransforming growth factor-beta antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. Intl. J. Rad. Oncol. 65:876-881.

Bagley RG, Rouleau C, Morgenbesser SD, Weber W, Cook BP, Shankara S, Madden SL, Teicher BA. 2006. Pericytes from human non-small cell lung carcinomas: An attractive target for anti-angiogenic therapy. Microvasc Res 71:163-174.

Bonate PL, Arthaud L, Cantrell WR, Stephenson K, Secrist JAr, Weitman S. 2006. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5:855-863.

Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. 2006. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: Strategy for treatment. Clin Cancer Res 12:4011-4017.

Huang B, Solomon S, Thangavelu M, Peters K, Bhatt S. 2006. Supernumerary marker chromosomes detected in 100,000 prenatal diagnoses: molecular cytogenetic studies and clinical significance. Prenat Diagn 26:1142-1150.

Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P. 2006. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24:1917-1923.

Lindner P, Cahlin C, Friman S, Hafstrom L, Klingenstierna H, Lonn L, Olausson M, Rizell M. 2006. Extended right-sided liver resection for colorectal liver metastases - Impact of percutaneous portal venous embolisation. Eur J. Surg. Oncol. 32:292-296.

Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QS, DeBono JS, Jones CB, Weitman S, Rowinsky EK. 2006. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res 12:5207-5215.

Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, Michalowska AM, Fisher LW, Fedarko NS, Jain A, Pinkas J, Lonning S, Wakefield LM. 2006. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 66:6327-6335.

Pinkas J, Teicher BA. 2006. TGF-beta in cancer and as a therapeutic target. Biochem Pharmacol.

Plog MS, Guyre CA, Roberts BL, Goldberg M, George JA, Perricone MA. 2006. Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery. Hum Gene Ther.

Robbins RJ, Driedger A, Magner J. 2006. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16:1121-1130.

Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL. 2006. Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H). Clin Canc Res 12:7174-7179.

Rouleau C, Roy A, St Martin T, Dufault MR, Boutin P, Liu D, Zhang M, Puorro-Radzwill K, Rulli L, Reczek D, Bagley R, Byrne A, Weber W, Roberts B, Klinger K, Brondyk W, Nacht M, Madden S, Burrier R, Shankara S, Teicher BA. 2006. Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: Expression and function. Mol Cancer Ther 5:219-229.

Schulmeier BE, Cantrell WR, Jr., Bauta WE. 2006. Preparation of a fludarabine intermediate via selective alkylation of 2-fluoroadenine. Nucleosides Nucleotides Nucleic Acids 25:735-745.

Teicher BA. 2006. Tumor models for efficacy determination. Mol Cancer Ther 5:2435-2443.

Teicher BA. 2006. Protein kinase C as a therapeutic target. Clin Cancer Res 12:5336-5345.

Zhang W, Garces J, Dong HY. 2006. Detection of the t(11;18) API2/MALT1 translocation associated with gastric MALT lymphoma in routine formalin-fixed, paraffin-embedded small endoscopic biopsy specimens by robust real-time RT-PCR. Am J Clin Pathol 126:931-940.

Agata N, Nogi H, Bamberg M, Milhollen M, Pu M, Weitman S, Kharbanda S, Kufe D. 2005. The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel. Cancer Chemotherapy & Pharmacology 56:610-614.

Bagley RG, Weber WD, Rouleau C, Teicher BA. 2005. Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. Cancer Res. 65:9741-9750.

Bonate PL. 2005. Covariate detection in population pharmacokinetics using partially linear mixed effects models. Pharm Res 22:541-549.

Bonate P, Arthaud L, Stuhler J, Yerino P, Press R, Rose J. 2005. The distribution, metabolism, and elimination of clofarabine in rats. Drug Metab Dispos 33:739-748.

Bonate PL, Keating M, Weitman S, Hillmen P, Mould DR. 2005. Population pharmacokinetics of alemtuzumab in patients with hematologic malignancies. Blood 106:831A.

Bonate PL. 2005. Recommended reading in population pharmacokinetic pharmacodynamics. AAPSJ 5:E363-373.

Chan EM, Comer EM, Brown FC, Richkind KE, Holmes ML, Chong BH, Shiffman R, Zhang DE, Slovak ML, Willman CL, Noguchi CT, Li Y, Heiber DJ, Kwan L, Chan RJ, Vance GH, Ramsey HC, Hromas RA. 2005. AML1-FOG2 fusion protein in myelodysplasia. Blood.

Corey SJ, Elopre M, Weitman S, Rytting ME, Robinson LJ, Rumelhart S, Goldman FD. 2005. Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol 27:166-168.

Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder Jr. JP. 2005. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin. Clin Cancer Res 11:7825-7833.

Dong HY, Liu W, Cohen P, Mahle CE, Zhang W. 2005. B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in merkel cell carcinoma and small cell carcinomas. Am J Surg Pathol 29:687-692.

Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL. 2005. Plasmablastic lymphoma in HIV-positive patients: An aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol 29:1633-1641.

Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A, Weitman S, Hammond LA. 2005. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 11:7807-7816.

Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. 2005. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105:940-947.

Gasparini G, Longo R, Fanelli M, Teicher BA. 2005. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23:1295-1311.

Horton TM, Blaney SM, Langevin A-M, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S. 2005. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: A pediatric oncology group study. Clin Cancer Res 11:1884-1889.

Kaplan JM. 2005. Adenovirus-based cancer gene therapy. Curr Gene Ther 5:595-605.

Lee PS, Beneck D, Weisberger J, Gorczyca W. 2005. Coexpression of CD43 by benign B cells in the terminal ileum. Appl Immunohistochem Mol Morphol 13:138-141.

Lew K. 2005. Cancer connections: Acute myeloid leukemia. J. Assoc. of Genet. Technologists 31:91-94.

Lotze M, Wang E, Marincola F, Hanna N, Bugelski P, Burns C, Coukos G, Damle N, Godfrey T, Howell W, Panelli M, Perricone M, Petricoin E, Sauter G, Scheibenbogen C, Shivers S, Taylor D, Weinstein J, Whiteside T. 2005. Workshop on cancer biometrics: Identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother 28:79-119.

Maclachlan TK, Pinkas J. 2005. Marine-derived cancer therapeutics making a splash. Cancer Biol Ther 4.

Reddy KS, Richkind K, Ross M, Seirra R. 2005. Translocation (X;20)(q13;q13.3): a nonrandom abnormality in four patients with myeloid disorders. Canc Genet & Cytogen 157:70-73.

Shah R, Rowland B, Richkind K, Mowery-Rushton P, Roherty S, Morgan R, Schlam M. 2005. Translocation (3;12)(q25;p11.2): a recurrent cytogenetic abnormality in acute myeloid leukemia. Cancer Genet Cytogenet 156:186-187.

Teicher BA. 2005. Hypoxia, tumor endothelium, and targets for therapy. Adv Exp Med Biol 566:31-38.

Teicher BA. 2005. Tumor models for preclinical development of targeted agents. Prog Drug Res 63:43-66.

Agata N, Nogi H, Milhollen M, Kharbanda S, Kufe D. 2004. 2-(8-Hydroxy-6-methoxy-1-oxo- 1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells. Cancer Res. 64:8512-8516.

Bauta WE, Schulmeier BE, Burke B, Puente JF, Cantrell WR, Lovett D, Goebel J, Anderson B, Ionescu D, Guo RC. 2004. A new process for antineoplastic agent clofarabine. J of Organic Proc. Res & Dev 8:889-896.

Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, Steinherz P, Weitman S. 2004. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol 44:1309-1322.

Dong HY. 2004. Antigenic variation of hairy cell leukemia defines a CD25 negative variant with a uniform immunophenotype and distinct clinicopathologic features. Blood 104:313A.

Dong HY. 2004. Subset of T-cell prolymphocytic leukemia expresses CD117. Blood. 104:218B.

Dong HY, Cohen P, Lee P-S. 2004. Biphenotypic gamma-delta T-cell leukemia/lymphoma with coexpression of Pax-5 and other B-cell specific antigens. Blood 104:221B.

Felten CL, Stephenson CF, Ortiz RO, Hertzberg L. 2004. Burkitt transformation of mantle cell lymphoma. Leuk Lymphoma 45:2143-2147

Francia G, Man S, Teicher B, Grasso L, Kerbel RS. 2004. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol 24:6837-6849.

Gorczyca W. 2004. Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukemia (AML-M5), acute myelomonocytic leukemia (AML-M4), and chronic myelomonocytic leukemia (CMML). Methods Cell Biol 75:665-677.

Gorczyca W. 2004. Differential diagnosis of T-cell lymphoproliferative disorders by flow cytometry multicolor immunophenotyping. correlation with morphology. Methods Cell Biol 75:595-621.

Gorczyca W, Dong HY, Weisberger J, Liu Z. 2004. Hypergranular non-M3 acute myelogenous leukemia: A potential pitfall in flow cytometric diagnosis. Blood 104:195B-196B.

Gorczyca W, Tugulea S, Liu Z, Li X, Wong JY, Weisberger J. 2004. Flow cytometry in the diagnosis of mediastinal tumors with emphasis on differentiating thymocytes from precursor T-lymphoblastic lymphoma/leukemia. Leuk Lymphoma 45:529-538.

Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. 2004. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res 10:7662-7670.

Huang Y, Franklin J, Gifford K, Roberts BL, Nicolette CA. 2004. A high-throughput proteo-genomics method to identify antibody targets associated with malignant disease. Clin Immun 111:202-209.

Kaplan JM. 2004. New cancer vaccine approaches. Drugs Today (Barc) 40:913-929.

Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D, Chen YF, Iversen P, Teicher BA. 2004. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 53:133-140.

Lobb KL, Hipskind PA, Aikins JA, Alvarez E, Cheung YY, Considine EL, De Dios A, Durst GL, Ferritto R, Grossman CS, Giera DD, Hollister BA, Huang Z, Iversen PW, Law KL, Li T, Lin HS, Lopez B, Lopez JE, Cabrejas LM, McCann DJ, Molero V, Reilly JE, Richett ME, Shih C, Teicher B, Wikel JH, White WT, Mader MM. 2004. Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem 47:5367-5380.

Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, Dufault MR, Zhang X, Zhang W, Walter-Yohrling J, Rouleau C, Akmaev VR, Wang CJ, Cao X, St Martin TB, Roberts BL, Teicher BA, Klinger KW, Stan RV, Lucey B, Carson-Walter EB, Laterra J, Walter KA. 2004. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 165:601-608.

Martin SS, Ridgeway AG, Pinkas J, Lu Y, Reginato MJ, Koh EY, Michelman M, Daley GQ, Brugge JS, Leder P. 2004. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene 23:4641-4645.

McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK. 2004. Report from the Society for Biological Therapy and Vascular Biology faculty of the NCI workshop on angiogenesis monitoring. J Immunother 27:161-175.

Montgomery KD, Winter SS, Frost JD, Hardekopf D, Holt K, Graham ML, Foucar K. 2004. Myeloid antigen positive acute lymphoblastic leukemia with the Philadelphia translocation and a jumping translocation of 1q in a child. Leukemia 18:1548-1550.

Nanda A, Buckhaults P, Seaman S, Agrawal N, Boutin P, Shankara S, Nacht M, Teicher B, Stampfl J, Singh S, Vogelstein B, Kinzler KW, St Croix B. 2004. Identification of a binding partner for the endothelial cell surface proteins TEM7 and TEM7R. Cancer Res 64:8507-8511.

Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, Saha S, Bardelli A, Jiang Y, St Martin TB, Nacht M, Teicher BA, Klinger KW, Sukumar S, Madden SL. 2004. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 64:7857-7866.

Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, St George JA, Kaplan JM. 2004. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 27:273-281.

Pinkas J, Martin SS, Leder P. 2004. Bcl-2-mediated cell survival promotes metastasis of EpH4 betaMEKDD mammary epithelial cells. Mol Cancer Res 2:551-556.

Sun G, Lorenzo M, Tripodi J, Chrysostomou C. 2004. Valuation of cytogenetics and FISH in evaluation of myelodysplastic syndromes: A cancer cytogenetics reference lab's experience. Blood 104:404A.

Teicher BA. 2004. Models for biomarkers and minimal residual tumor. In: In: Anticanc Drug Dev Guide (2nd Edition): Humana Press. p 243-258.

Teicher BA, Andrews PA, editors. 2004. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition: Humana Press.

Teicher BA, Andrews PA. 2004. Preclinical models for combination therapy. In: Anticancer Development Guide: 2nd Edition Preclinical Screening, Clinical Trials and Approval, Second ed: Humana Press.

Vigushin DM, Dong Y, Inman L, Peyvandi N, Alao JP, Sun C, Ali S, Niesor EJ, Bentzen CL, Coombes RC. 2004. The nuclear oxysterol receptor LXRalpha is expressed in the normal human breast and in breast cancer. Med Oncol 21:123-131.

Walter-Yohrling J, Morgenbesser S, Rouleau C, Bagley R, Callahan M, Weber W, Teicher BA. 2004. Murine endothelial cell lines as models of tumor endothelial cells. Clin Cancer Res 10:2179-2189.

Yamakawa M, Liu LX, Belanger AJ, Date T, Kuriyama T, Goldberg MA, Cheng SH, Gregory RJ, Jiang C. 2004. Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis. Am J Physiol Renal Physiol 287:F649-657.

Yano M, Nakashima Y, Kobayashi Y, Mizuno K, Konishi A, Sasaki H, Fukai I, Scheule RK, Fujii Y. 2004. Endostatin gene transfection using a cationic lipid: advantages of transfection before tumor cell inoculation and repeated transfection. Cancer Gene Ther 11:354-362.

Zhao J, Huang L, Belmar N, Buelow R, Fong T. 2004. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res 10:2851-2859.

Alvarez E, Westmore M, Galvin R, Clapp C, Considine E, Smith S, Keyes K, Iversen P, Delafuente D, Sulaimon S, Zambrano C, Ma L, Sato M, Martin T, Teicher B, Galbreath E. 2003. Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption. Clin Cancer Res 9:5705-5713.

Bagley RG, Walter-Yohrling J, Cao X, Weber W, Simons B, Cook BP, Chartrand SD, Wang C, Madden SL, Teicher BA. 2003. Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells. Cancer Res 63:5866-5873.

Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, Kumar R. 2003. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112:785-794.

Jiang Y, Zhang W, Kondo K, Klco JM, St Martin TB, Dufault MR, Madden SL, Kaelin WG, Jr., Nacht M. 2003. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res 1:453-462.

Keyes KA, Mann L, Cox K, Treadway P, Iversen P, Chen YF, Teicher BA. 2003. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol 51:321-327.

Keyes KA, Mann L, Teicher B, Alvarez E. 2003. Site-dependent angiogenic cytokine production in human tumor xenografts. Cytokine 21:98-104.

Nicolette CA, Miller GA. 2003. The identification of clinically relevant markers and therapeutic targets. Drug Discov Today 8:31-38.

Okunieff P, Meyn RE, Teicher BA, Thomas CR, Jr., Gaspar LE, Raben D, Giri S, Lavey RS, Turrisi AT, 3rd, Swanson GP, Smalley SR. 2003. Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003. Am J Clin Oncol 26:522-529.

Ramsey H, Zhang DE, Richkind K, Burcoglu-O'Ral A, Hromas R. 2003. Fusion of AML1/Runx1 to copine VIII, a novel member of the copine family, in an aggressive acute myelogenous leukemia with t(12;21) translocation. Leukemia 17:1665-1666.

Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM. 2003. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 7:498-505.

Teicher BA. 2003. The role of platinum complexes in combined modality therapy. In: Choy H, editor. Chemorad in CancTher: Humana Press. p 47-63.

Teicher BA. 2003. Assays for in vitro and in vivo synergy. Methods Mol Med 85:297-321.

Terabe M, Matsui S, Park J, Mamura M, Noben-Trauth N, Donaldson D, Chen W, Wahl S, Ledbetter S, Pratt B, Letterio J, Paul W, Berzofsky J. 2003. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 198:1741-1752.

Walter-Yohrling J, Cao X, Callahan M, Weber W, Morgenbesser S, Madden S, Wang CJ, Teicher BA. 2003. Identification of genes expressed in malignant cells that promote invasion. Cancer Res 63:8939-8947.

Walter-Yohrling J, Pratt BM, Ledbetter S, Teicher BA. 2003. Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model. Cancer Chemother Pharmacol 52:263-269.

Baigent G, Barngrover D. 2002. Recombinant interleukin-2 (aldesleukin) for oncology and HIV disease and recombinant protein treatment (Fabrazyme) for Fabry's disease (No. 14 in a series of articles to promote a better understanding of the use of genetic engineering). J Biotech 95:277-283.

Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Gronberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J. 2002. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30:181-184.

De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA, Schiavi SC. 2002. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17:1102-1110.

Hempel DM, Smith KA, Claussen KA, Perricone MA. 2002. Analysis of cellular immune responses in the peripheral blood of mice using real-time RT-PCR. J Immunol Methods 259:129-138.

Housseau F, Lindsey KR, Oberholtzer SD, Gonzales MI, Boutin P, Moorthy AK, Shankara S, Roberts BL, Topalian SL. 2002. Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients. J Immunol Methods 266:87-103.

Keyes K, Cox K, Treadway P, Mann L, Shih C, Faul MM, Teicher BA. 2002. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res 62:5597-5602.

Lawendowski CA, Giurleo GM, Huang YY, Franklin GJ, Kaplan JM, Roberts BL, Nicolette CA. 2002. Solid-phase epitope recovery: a high throughput method for antigen identification and epitope optimization. J Immunol 169:2414-2421.

Richkind KE, Mortimer E, Mowery-Rushton P, Fraire A. 2002. Translocation (16;20)(p11.2;q13). sole cytogenetic abnormality in a unicameral bone cyst. Cancer Genet Cytogenet 137:153-155.

Ruzek MC, Kavanagh BF, Scaria A, Richards SM, Garman RD. 2002. Adenoviral vectors stimulate murine natural killer cell responses and demonstrate antitumor activities in the absence of transgene expression. Mol Ther 5:115-124.

Siders WM, Vergillis K, Johnson C, Scheule RK, Kaplan JM. 2002. Tumor treatment with complexes of cationic lipid and noncoding plasmid DNA results in the induction of cytotoxic T cells and systemic tumor elimination. Mol Ther 6:519-527.

Thangavelu M, Huang B, Lemieux M, Tom W, Richkind KE. 2002. A t(4;11)(q21;p15) in a case of T-cell lymphoma and a case of acute myelogenous leukemia. Cancer Genet Cytogenet 132:109-115.

Bianchi DW, Farina A, Weber W, Delli-Bovi LC, Deriso M, Williams JM, Klinger KW. 2001. Significant fetal-maternal hemorrhage after termination of pregnancy: implications for development of fetal cell microchimerism. Am J of Obstet Gyne 184:703-706.

Hromas R, Busse T, Carroll A, Mack D, Shopnick R, Zhang DE, Nakshatri H, Richkind K. 2001. Fusion AML1 transcript in a radiation-associated leukemia results in a truncated inhibitory AML1 protein. Blood 97:2168-2170.

Krohne TU, Shankara S, Geissler M, Roberts BL, Wands JR, Blum HE, Mohr L. 2001. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 34:511-518.

Mohr L, Yoon SK, Eastman SJ, Chu Q, Scheule RK, Scaglioni PP, Geissler M, Heintges T, Blum HE, Wands JR. 2001. Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinomas in mice. Hum Gene Ther 12:799-809.

Nacht M, Dracheva T, Gao Y, Fujii T, Chen Y, Player A, Akmaev V, Cook B, Dufault M, Zhang M, Zhang W, Guo M, Curran J, Han S, Sidransky D, Buetow K, Madden SL, Jen J. 2001. Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci U S A 98:15203-15208.

Rudginsky S, Siders W, Ingram L, Marshall J, Scheule R, Kaplan J. 2001. Antitumor activity of cationic lipid complexed with immunostimulatory DNA. Mol Ther 4:347-355.

Sood R, Bonner TI, Makalowska I, Stephan DA, Robbins CM, Connors TD, Morgenbesser SD, Su K, Faruque MU, Pinkett H, Graham C, Baxevanis AD, Klinger KW, Landes GM, Trent JM, Carpten JD. 2001. Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus. Genomics 73:211-222.

Varella-Garcia M, Hogan CJ, Odom LF, Murata-Collins JL, Ai H, Chen L, , Richkind K, Paskulin G, Andreeff M, Brizard AM, L., Gemmill RM, Berger R, Drabkin HA. 2001. Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. Leukemia 15:1408-1414.

Yoon SK, Armentano D, Wands JR, Mohr L. 2001. Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice. Cancer Gene Ther 8:573-579.